Back
HFA Premium Access

Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: insights from the CANVAS Program and CREDENCE trial

Session: Chronic heart failure - pharmacotherapy 6
Topic: Pharmacotherapy
Speaker: Doctor A. Sharma (Montreal, CA)
Event: Heart Failure 2023

Congress Presentation

Add to my library

Like

About the speaker

Doctor Abhinav Sharma

McGill University Health Centre, Montreal (Canada)
3 presentations
0 follower

5 more presentations in this session

Total cholesterol decrease associates with higher mortality in chronic heart failure

Speaker: Doctor M. Rocha (Porto, PT)

Access
Abstract
Slides
Like
Thumbnail

Safety, pharmacokinetics, and pharmacodynamics of AZD3427, a functionally selective long acting relaxin mimetic agonist of the RXFP1 receptor

Speaker: Professor M. Ufnal (Gothenburg, SE)

Access
Abstract
Slides
Like
Thumbnail

Hypoalbuminemia increases the time to euvolemia in heart failure patients

Speaker: Doctor I. Fialho (Lisbon, PT)

Access
Abstract
Slides
Like
Thumbnail

A budget impact analysis of empagliflozin for heart failure patients with full spectrum of ejection fraction in South Korea

Speaker: Doctor J. Youn (Seoul, KR)

Access
Abstract
Slides
Like
Thumbnail

Long-acting relaxin (LY3540378) demonstrates improved renal hemodynamics response in preclinical and clinical studies

Speaker: Doctor X. Wang (Indianapolis, US)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Chronic heart failure - pharmacotherapy 6

Speakers: Doctor A. Sharma, Doctor M. Rocha, Professor M. Ufnal, Doctor I. Fialho, Doctor J. Youn...
Access
Like
Thumbnail

About the event

Image

Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources